University of California Berkeley seal E. O. Lawrence Berkeley National Laboratory seal
The Carcinogenic Potency Project

1,2-Dibromoethane (CAS 106-93-4)
SMILES, InChI and Structure are below.
Rats and Mice: Cancer Test Summary
Rat Target Sites Mouse Target Sites TD50 (mg/kg/day)
Male Female Male Female Rat Mouse
nas per pit sto vsc liv lun mgl nas pit sto vsc lun sto vsc eso lun mgl nas sto sub vsc 1.52m 7.45m,v

Key to the Table Above

Positivity: For each chemical with a positive (carcinogenic) experiment in the Carcinogenic Potency Database (CPDB), results are included on carcinogenic potency (TD50) in each species and target sites in males and females. Positivity is determined by an author’s opinion in a published paper. If all experimental results in the CDPB are negative in a sex-species group, “no positive” appears. If the CPDB has no experiments in the sex-species group, “no test” appears. The summary presents the strongest evidence of carcinogenicity in each group. If there are both positive and negative experiments in a sex-species, the negative results are ignored in this Summary Table.
Target Site Codes:   eso = esophagus. liv = liver. lun = lung. mgl = mammary gland. nas = nasal cavity (includes tissues of the nose, nasal turbinates, paranasal sinuses and trachea). per = peritoneal cavity. pit = pituitary gland. sto = stomach. sub = subcutaneous tissue. vsc = vascular system. Target sites are listed if any author of published experimental results concluded that tumors were induced in that organ by the test agent. If there is more than one positive experiment in a sex-species, target sites listed may be from more than one experiment, e.g. if liver and lung are both listed, then liver may have been a target in one experiment and lung in another.
TD50: Our standardized measure of carcinogenic potency, TD50, is the daily dose rate in mg/kg body weight/day to induce tumors in half of test animals that would have remained tumor-free at zero dose. Whenever there is more than one positive experiment in a species, the reported TD50 value is a Harmonic Mean calculated using the TD50 value from the most potent target site in each positive experiment.
Superscripts:   m = There is more than one positive experiment in the species, and TD50 values from each positive experiment are used in the calculation of the reported Harmonic mean of TD50. v = Variation is greater than ten-fold among statistically significant (two-tailed p<0.1) TD50 values from different positive experiments.

The Carcinogenic Potency Database (CPDB) is a unique and widely used international resource of the results of 6540 chronic, long-term animal cancer tests on 1547 chemicals. The CPDB provides easy access to the bioassay literature, with qualitative and quantitative analyses of both positive and negative experiments that have been published over the past 50 years in the general literature through 2001 and by the National Cancer Institute/National Toxicology Program through 2004. The CPDB standardizes the diverse literature of cancer bioassays that vary widely in protocol, histopathological examination and nomenclature, and in the published author’s choices of what information to provide in their papers. Results are reported in the CPDB for tests in rats, mice, hamsters, dogs, and nonhuman primates.

For each experiment, information is included on species, strain, and sex of test animal; features of experimental protocol such as route of administration, duration of dosing, dose level(s) in mg/kg body weight/day, and duration of experiment; experimental results are provided on target organ, tumor type, and tumor incidence; carcinogenic potency (TD50) and its statistical significance; shape of the dose-response, author’s opinion as to carcinogenicity, and literature citation.

Only tests with dosing for at least ¼ the standard lifespan of the species and experiment length at least ½ the lifespan are included in the CPDB. Only routes of administration with whole body exposure are included. Doses are standardized, average dose rates in mg/kg/day. A description of methods used in the CPDB to standardize the diverse literature of animal cancer tests is presented for: 1) Criteria for inclusion of experiments 2) Standardization of average daily dose levels and 3) TD50 estimation for a standard lifespan. See Methods for other details.

TD50 provides a standardized quantitative measure that can be used for comparisons and analyses of many issues in carcinogenesis. The range of TD50 values across chemicals that are rodent carcinogens is more than 100 million-fold. More than half the chemicals tested are positive in at least one experiment.

A plot of all results on each experiment in the CPDB for this chemical is presented below. These results are the source information for the Cancer Test Summary table above.

1,2-Dibromoethane: All Experiments and Citations in CPDB

The definition of each code in the plot below will appear in a pop-up window when the field name in the header line is clicked, e.g., Strain, Site, Path. Each numbered line starts a new experiment and reports protocol information in black. Average daily dose-rates per kg body weight per day are in green. Remaining lines report experimental results in blue.

Abbreviations of fields in header line: # = the line number in the plot of all CPDB chemicals; Xpo = duration of dosing; Xpt = duration of experiment; Site = tissue; Path = tumor type; DR = dose-response; AuOp = author’s opinion about carcinogenicity; LoConf, UpConf = confidence limits (99%) on TD50; Inc = tumor incidence for each dose group.

See Guide to reading the plot for details on each field, using an example of one experiment.

See Help to improve readability, or to fit the plot onto the screen or a printed page.

Chemical (Synonym) CAS
# Species Sex Strain Route Xpo+Xpt PaperNum        0 Dose  1 Dose 2 Dose  3 Dose          Literature Reference or NCI/NTP:Site Path
Site Path Notes   TD50  DR Pval    AuOp LoConf UpConf   Cntrl   1 Inc  2 Inc   3 Inc                                                        Brkly Code

1,2-DIBROMOETHANE (ethylene dibromide, EDB) 106-93-4 1882 M f b6c inh 22m24 TR210 : 0 23.9mg 95.6mg MXB MXB s 9.60mg / P<.0005 6.41mg 14.8mg 6/50 31/50 47/50 ---:hem,hes; lun:a/a,a/c,adn,apn,can; mgl:acn; nas:---, adn,apn,can; sub:fbs. C lun MXA s 18.4mg / P<.0005 c 11.3mg 30.9mg 4/50 11/50 42/50 lun:a/a,a/c,adn,apn,can. lun MXA s 18.7mg / P<.0005 c 11.4mg 31.6mg 4/50 11/50 41/50 lun:a/a,a/c. --- MXA s 24.1mg / P<.0005 c 14.1mg 41.6mg 0/50 12/50 25/50 ---:hem,hes. --- hes s 25.7mg / P<.0005 c 14.7mg 45.6mg 0/50 11/50 23/50 mgl acn s 26.2mg * P<.0005 c 13.7mg 61.7mg 2/50 14/50 8/50 lun a/c s 30.3mg / P<.0005 c 18.0mg 50.3mg 1/50 5/50 37/50 lun a/a s 38.6mg / P<.0005 c 18.6mg 98.3mg 3/50 7/50 13/50 sub fbs s 90.7mg * P<.0005 c 41.5mg 0/50 4/50 11/50 l/b MXA s * P<.0005 64.5mg 0/50 1/50 8/50 l/b:adn,can. S nas --- s / P<.0005 c 89.0mg 0/50 0/50 12/50 --- hem s * P<.0005 81.6mg 1.18gm 0/50 1/50 4/50 S l/b can s * P<.002 74.7mg 1.51gm 0/50 1/50 4/50 S l/b MXA s / P<.0005 0/50 0/50 6/50 l/b:adn,apn. S nas MXA s * P<.0005 c 0/50 0/50 8/50 nas:adn,can. nas MXA s * P<.0005 c 1.57gm 0/50 0/50 5/50 nas:adn,apn. l/b adn s * P<.0005 1.55gm 0/50 0/50 5/50 S nas can s * P<.0005 c 1.67gm 0/50 0/50 6/50 nas apn s * P<.004 c 4.80gm 0/50 0/50 3/50 TBA MXB s 6.83mg / P<.0005 4.55mg 10.9mg 23/50 45/50 49/50 liv MXB s * P<.07 31.4mg n.s.s. 2/50 6/50 1/50 liv:hpa,hpc,nnd. lun MXB s 18.7mg / P<.0005 11.4mg 31.6mg 4/50 11/50 41/50 lun:a/a,a/c. 1883 M f b6c gav 53w78 TR86 : 0 26.0mg 52.0mg MXB MXB sv 3.74mg * P<.0005 2.58mg 6.93mg 0/20 46/50 30/50 lun:a/a,a/c; sto:sqc. C sto sqc sv 4.07mg * P<.0005 c 2.81mg 8.09mg 0/20 46/50 28/50 lun MXA sv 15.4mg * P<.04 c 8.06mg n.s.s. 0/20 11/50 6/50 lun:a/a,a/c. lun a/a sv 17.3mg * P<.03 c 8.85mg n.s.s. 0/20 10/50 6/50 TBA MXB sv 3.52mg * P<.0005 2.42mg 6.31mg 0/20 47/50 31/50 liv MXB sv no dre P=1. n.s.s. n.s.s. 0/20 1/50 0/50 liv:hpa,hpc,nnd. lun MXB sv 15.4mg * P<.04 8.06mg n.s.s. 0/20 11/50 6/50 lun:a/a,a/c. 1884 M f b6c wat 73w73 1761 0 Van Durren;tcam,5,393-403;1985 for mix e 13.1mg P<.0005 + 6.68mg 25.7mg 1/50 27/29 for sqc e 24.5mg P<.0005 + 13.9mg 46.5mg 0/50 22/29 eso sqp e P<.02 + 96.3mg n.s.s. 0/50 3/29 lun ptm e 2.34gm P<.7 - n.s.s. 1/50 1/29 liv tum e no dre P=1. - n.s.s. 0/50 0/29 tba mix e 13.8mg P<.0005 6.84mg 28.6mg 7/50 27/29 1885 M f b6c wat 78w78 1806 0 48.0mg Van Duuren;enhp,69,109-117;1986 for pam e 23.2mg P<.0005 13.9mg 44.8mg 9/96 29/49 for sqc e 35.3mg P<.0005 + 20.7mg 67.1mg 0/96 20/49 eso pam e P<.004 75.0mg 1.58gm 0/96 4/49 liv hpt e no dre P=1. n.s.s. 2/96 0/49 lun ptm e no dre P=1. n.s.s. 13/96 2/49 tba mix e noTD50 P<.2 n.s.s. n.s.s. 84/96 49/49 1886 M m b6c inh 78w78 TR210 : 0 19.9mg 79.5mg MXB MXB 18.0mg * P<.0005 11.3mg 32.5mg 0/50 3/50 26/50 ---:hem,hes; lun:---,a/a,a/c. C lun --- 18.2mg * P<.0005 c 11.4mg 33.6mg 0/50 3/50 25/50 lun MXA 21.0mg * P<.0005 c 13.0mg 40.2mg 0/50 3/50 23/50 lun:a/a,a/c. lun a/c 24.7mg * P<.0005 c 14.7mg 53.7mg 0/50 3/50 19/50 lun a/a 60.1mg * P<.0005 c 29.9mg 0/50 0/50 11/50 MXA apn * P<.02 47.1mg n.s.s. 0/50 0/50 5/50 b/l:apn; l/b:apn. S l/b MXA * P<.02 47.1mg n.s.s. 0/50 0/50 5/50 l/b:adn,apn. S --- MXA * P<.03 c 67.2mg n.s.s. 0/50 0/50 4/50 ---:hem,hes. l/b apn * P<.05 65.7mg n.s.s. 0/50 0/50 3/50 S TBA MXB 21.2mg * P<.0005 11.7mg 65.5mg 3/50 5/50 27/50 liv MXB no dre P=1. 87.5mg n.s.s. 3/50 1/50 3/50 liv:hpa,hpc,nnd. lun MXB 21.0mg * P<.0005 13.0mg 40.2mg 0/50 3/50 23/50 lun:a/a,a/c. 1887 M m b6c gav 53w78 TR86 : 0 30.0mg 53.0mg MXB MXB esv 2.34mg * P<.0005 1.07mg 4.23mg 0/20 45/50 33/50 lun:a/a; sto:sqc,sqp. C sto MXA esv 2.36mg * P<.0005 c 1.07mg 4.32mg 0/20 45/50 31/50 sto:sqc,sqp. sto sqc esv 2.38mg * P<.0005 c 1.08mg 4.43mg 0/20 45/50 29/50 lun a/a esv 13.4mg * P<.003 c 4.58mg 55.8mg 0/20 4/50 10/50 TBA MXB esv 2.66mg * P<.0005 1.19mg 5.83mg 2/20 45/50 33/50 liv MXB esv no dre P=1. 51.5mg n.s.s. 2/20 1/50 1/50 liv:hpa,hpc,nnd. lun MXB esv 13.4mg * P<.003 4.58mg 55.8mg 0/20 4/50 10/50 lun:a/a,a/c. 1888 M m b6c wat 65w65 1761 0 Van Durren;tcam,5,393-403;1985 for sqc e 11.8mg P<.0005 + 5.98mg 23.1mg 0/45 26/28 for mix e 11.9mg P<.0005 + 6.01mg 23.5mg 1/45 26/28 liv tum e no dre P=1. n.s.s. 0/45 0/28 lun ptm e no dre P=1. - n.s.s. 5/45 2/28 tba mix e 12.7mg P<.0005 6.21mg 27.4mg 8/45 26/28 1889 M m b6c wat 78w78 1806 0 46.7mg Van Duuren;enhp,69,109-117;1986 for sqc e 9.44mg P<.0005 + 5.97mg 15.5mg 2/99 41/48 eso sqc e P<.003 71.4mg 1.40gm 0/99 4/48 eso pam e P<.003 71.4mg 1.40gm 0/99 4/48 liv hpt e no dre P=1. n.s.s. 12/99 1/48 tba mix e noTD50 P<.05 n.s.s. n.s.s. 76/99 48/48 1890 R f f34 inh 23m24 TR210 : 0 5.71mg 22.8mg MXB MXB as 1.81mg / P<.0005 1.27mg 2.71mg 6/50 44/50 45/50 ---:hes; lun:a/a,a/c; mgl:fba; nas:---,acn,adn,apn,can, sqc; pit:adn; spl:hes. C nas --- as 2.33mg / P<.0005 c 1.64mg 3.43mg 1/50 34/50 43/50 mgl fba as 3.60mg / P<.0005 c 2.37mg 5.91mg 4/50 29/50 24/50 nas acn as 4.28mg / P<.0005 c 2.81mg 6.78mg 0/50 20/50 29/50 pit adn as 7.46mg * P<.0005 c 4.25mg 16.0mg 1/50 18/50 4/50 nas adn as 10.8mg * P<.0005 c 5.67mg 24.0mg 0/50 11/50 3/50 nas can as 21.6mg / P<.0005 c 13.0mg 38.3mg 0/50 0/50 25/50 nas apn as 22.9mg * P<.0005 c 10.0mg 62.4mg 0/50 5/50 5/50 nas sqc as 54.2mg / P<.002 c 18.6mg 1/50 1/50 5/50 liv hpc as 66.4mg * P<.002 20.4mg 0/50 1/50 3/50 S lun MXA as 83.5mg * P<.0005 c 30.9mg 0/50 0/50 5/50 lun:a/a,a/c. spl hes as 87.3mg * P<.0005 c 31.8mg 0/50 0/50 5/50 --- hes as 87.3mg * P<.0005 c 31.8mg 0/50 0/50 5/50 lun a/c as 99.9mg * P<.002 c 33.6mg 0/50 0/50 4/50 sub fib as * P<.008 47.7mg 4.00gm 0/50 0/50 3/50 S sub MXA as * P<.008 47.7mg 4.00gm 0/50 0/50 3/50 sub:fbs,fib. S mgl acn as 98.8mg / P<.02 26.5mg 27.1gm 1/50 0/50 4/50 S TBA MXB as 2.02mg / P<.0005 1.36mg 3.30mg 33/50 49/50 48/50 liv MXB as 45.6mg / P<.003 16.0mg 2/50 1/50 5/50 liv:hpa,hpc,nnd. 1891 R f osm gav 50w61 TR86 : 0 26.7mg 28.1mg sto sqc ades 1.26mg * P<.0005 c .665mg 2.14mg 0/20 40/50 29/50 MXB MXB ades 1.26mg * P<.0005 .665mg 2.14mg 0/20 40/50 29/50 liv:hpc,nnd; sto:sqc. C liv MXA ades 5.38mg / P<.0005 c 1.51mg 32.8mg 0/20 1/50 6/50 liv:hpc,nnd. liv hpc ades 5.52mg / P<.0005 c 1.52mg 38.6mg 0/20 1/50 5/50 adr MXA ades 20.9mg / P<.02 5.40mg n.s.s. 0/20 0/50 4/50 adr:coa,coc. S TBA MXB ades 1.19mg * P<.0005 .628mg 2.23mg 2/20 40/50 29/50 liv MXB ades 5.38mg / P<.0005 1.51mg 32.8mg 0/20 1/50 6/50 liv:hpa,hpc,nnd. 1892 R m f34 inh 22m24 TR210 : 0 4.00mg 15.9mg MXB MXB as 1.10mg / P<.0005 .787mg 1.60mg 1/50 43/50 48/50 nas:---,acn,adn,apn,can; nse:sqp; pit:adn; spl:hes; tnv: men,mso. C MXA MXA as 1.23mg / P<.0005 c .872mg 1.79mg 0/50 39/50 41/50 nas:---; nse:sqp. nas acn as 2.73mg / P<.0005 c 1.78mg 4.36mg 0/50 20/50 28/50 nas apn as 3.97mg * P<.0005 c 2.34mg 7.45mg 0/50 18/50 5/50 tnv mso as 5.63mg / P<.0005 c 3.36mg 10.1mg 1/50 8/50 25/50 tnv men as 6.06mg / P<.0005 c 3.61mg 10.6mg 0/50 7/50 25/50 nas adn as 7.66mg * P<.0005 c 3.84mg 19.7mg 0/50 11/50 0/50 pit adn as 13.8mg * P<.0005 c 6.07mg 46.3mg 0/50 7/50 2/50 spl hes as 16.5mg / P<.0005 c 8.48mg 33.7mg 0/50 1/50 15/50 nas can as 18.0mg / P<.0005 c 10.4mg 33.2mg 0/50 0/50 21/50 mul msm as 18.5mg * P<.003 7.21mg 0/50 5/50 1/50 S slg sar as 58.8mg * P<.004 17.3mg 0/50 1/50 3/50 S thy MXA as 86.1mg * P<.004 24.6mg 0/50 0/50 3/50 thy:fca,fcc. S TBA MXB as 1.34mg / P<.0005 .904mg 2.14mg 30/50 48/50 49/50 liv MXB as 78.5mg * P<.06 15.3mg n.s.s. 0/50 1/50 1/50 liv:hpa,hpc,nnd. 1893 R m osm gav 40w49 TR86 : () 0 27.4mg 29.2mg MXB MXB adsv 1.64mg / P<.0005 1.18mg 2.33mg 0/20 45/50 34/50 ---:hes; sto:sqc. C sto sqc adsv 1.65mg / P<.0005 c 1.18mg 2.35mg 0/20 45/50 33/50 --- hes adsv 9.62mg * P<.002 c 4.98mg 21.1mg 0/20 11/50 4/50 thy MXA adsv 10.4mg / P<.002 5.20mg 34.2mg 0/20 5/50 8/50 thy:fca,fcc. S TBA MXB adsv 1.56mg / P<.0005 1.12mg 2.22mg 0/20 46/50 35/50 liv MXB adsv 23.8mg * P<.03 8.97mg n.s.s. 0/20 3/50 2/50 liv:hpa,hpc,nnd. 1894 R f cdr inh 78w78 1032 0 13.4mg Wong;txap,63,155-165;1982/Plotnick pers.comm. nas tum e 2.20mg P<.0005 + 1.31mg 3.75mg 0/47 38/42 nas ben e 5.02mg P<.0005 + 3.09mg 8.79mg 0/47 27/42 nas mal e 8.59mg P<.0005 + 4.96mg 16.7mg 0/47 19/42 mgl car 19.9mg P<.0005 + 9.95mg 49.5mg 0/48 11/48 liv hpc 59.4mg P<.02 20.5mg n.s.s. 0/48 4/48 spl hes P<.1 29.9mg n.s.s. 0/48 2/48 1895 R m cdr inh 78w78 1032 0 9.39mg nas tum e 1.19mg P<.0005 + .645mg 2.11mg 0/47 40/42 nas ben e 2.52mg P<.0005 + 1.57mg 4.27mg 0/47 32/42 nas mal e 3.52mg P<.0005 + 2.17mg 6.15mg 0/47 27/42 spl hes 12.6mg P<.0005 + 6.47mg 29.7mg 0/48 12/48 bra mng 56.1mg P<.04 17.0mg n.s.s. 0/48 3/48 liv hpc 85.1mg P<.1 20.9mg n.s.s. 0/48 2/48

Mutagenicity in Salmonella: positive
SMILES Code for 1,2-Dibromoethane: BrCCBr
InChI Code for 1,2-Dibromoethane: InChI=1/C2H4Br2/c3-1-2-4/h1-2H2
Source for SMILES and InChI: USEPA Distributed Structure-Searchable Toxicity (DSSTox) Database
Chemical Structure for 1,2-Dibromoethane: Chemical Structure
Source for structure: National Library of Medicine ChemIDPlus

See full CPDB Summary Table on 1547 chemicals. See Full CPDB for all results on 6540 experiments of 1547 chemicals.

A complete list of CPDB chemicals, which is searchable by name or by CAS number, is available here.

For a compendium of CPDB results organized by target organ, which lists all chemicals in each species that induced tumors in each of 35 organs, see Summary Table by Target Organ.

The CPDB is available in several formats that permit printing and downloading into spreadsheets and statistical databases.

  1. A plot of the CPDB presents results of 1547 experiments on 6540 chemicals in an easily readable format that has been used in publications of the CPDB.
  2. A Screen version plot for use on a single computer screen, with the same data.
  3. Excel version of the same data.
  4. Tab-separated versions of the same data, which can be easily read into databases.

A Supplementary Dataset gives details on dosing and survival for each experiment.

Relatively precise estimates of the lower confidence limit on the TD10 (LTD10) are readily calculated from the TD50 and its lower confidence limit, which are reported in the CPDB. For researchers and regulatory agencies interested in LTD10 values, we provide them in an Excel spreadsheet.

PDF versions of our publications of analyses using the CPDB are available, organized by year and by research topic.

Carcinogenic Potency Database Project (CPDB) Home Page
For more information about this Web Page, contact Specialized Information Services (
Last updated: October 3, 2007

PDF documents are best viewed with the free Adobe® Reader
Excel documents are best viewed with the free Excel® Viewer